Adicet Bio Files 8-K Report

TL;DR

Adicet Bio dropped an 8-K, likely with financials and other updates.

AI Summary

On December 19, 2024, Adicet Bio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific material events or financial figures beyond the filing date were detailed in the provided text.

Why It Matters

This 8-K filing indicates Adicet Bio is providing updated information to the SEC, which could include financial statements or disclosures about significant company events.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report, and the provided text does not contain information about significant negative events or financial distress.

Key Players & Entities

• Adicet Bio, Inc. (company) — Registrant
• December 19, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• Boston, Massachusetts (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share ACET The Nasdaq Global Ma

Filing Documents

• acet-20241219.htm (8-K) — 47KB
• acet-ex99_1.htm (EX-99.1) — 22KB
• img94724212_0.jpg (GRAPHIC) — 2KB
• 0000950170-24-138419.txt ( ) — 190KB
• acet-20241219.xsd (EX-101.SCH) — 24KB
• acet-20241219_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On December 19, 2024, Adicet Bio, Inc. (Adicet or the Company) issued a press release titled "Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/ Advanced Clear Cell Renal Cell Carcinoma," a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. On December 19, 2024 the Company announced the first patient dosed in the Phase 1 clinical trial evaluating ADI-270 in metastatic/ advanced clear cell renal cell carcinoma (ccRCC). The Company plans to report preliminary clinical data from this Phase 1 trial of ADI-270 in ccRCC in the first half of 2025.

Forward-Looking Statements

Forward-Looking Statements The disclosure under this Item 8.01 contains "forward-looking statements" of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and operations of Adicet. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding Adicet's expectations for its Phase 1 trial of ADI-270 in metastatic/ advanced ccRCC, including plans to report preliminary clinical data in the first half of 2025. Any forward-looking statements in this Item 8.01 are based on management's current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including without limitation, the effect of global economic conditions and public health crises on the Company's business and financial results, including with respect to disruptions to its preclinical and clinical studies, business operations, employee hiring and retention, and ability to raise additional capital; Adicet's ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; that positive results, including interim results, from a preclinical or clinical study may not necessarily be predictive of the results of future or ongoing studies; that clinical studies may fail to demonstrate adequate safety and efficacy of Adicet's product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization; and regulatory approval proces

01 Exhibits

Item 9.01 Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by Adicet Bio, Inc. on December 19, 2024, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ADICET BIO, INC. Date: December 19, 2024 By: /s/ Nick Harvey Name: Nick Harvey Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR